ARS Pharmaceuticals Announces neffy Meets Primary Endpoints And Shows Rapid Symptom Control In Phase 2 Urticaria Clinical Study
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced positive results from a Phase 2 study of neffy, an investigational epinephrine nasal spray, for treating chronic spontaneous urticaria, a skin disorder. The study met its primary endpoints, showing significant improvement in symptoms as early as 5 minutes after dosing. The data supports further development of neffy, with an outpatient study for acute flares planned for 2024 and a pivotal study potentially starting in 2025.
February 26, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals announced positive Phase 2 results for neffy in treating chronic spontaneous urticaria, supporting its further development.
Positive Phase 2 results for a drug can significantly impact a biopharmaceutical company's stock price, especially when it addresses a treatment gap. The announcement of further development and future studies indicates confidence in the drug's potential, likely leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100